+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Synergistic effects of combination of FK463 with amphotericin B Enhanced efficacy in murine model of invasive pulmonary aspergillosis



Synergistic effects of combination of FK463 with amphotericin B Enhanced efficacy in murine model of invasive pulmonary aspergillosis



Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 40: 388




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035809055

Download citation: RISBibTeXText


Related references

Pathological findings in a murine pulmonary aspergillosis model Treatment with FK463, amphotericin B and a combination of FK463 and amphotericin B. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 40: 387, 2000

Efficacy of combination antifungal therapy with intraperitoneally administered micafungin and aerosolized liposomal amphotericin B against murine invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 53(8): 3508-3510, 2009

Pretreatment with itraconazole attenuates the efficacy of increasing amphotericin B dosages in a murine model of invasive pulmonary aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 41: 398, 2001

Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 52(11): 4178-4180, 2008

Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy 46(10): 3208-3214, 2002

Combination antifungal therapy with FK463 plus amphotericin B in treatment of experimental pulmonary aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 39: 581, 1999

Efficacy of FK463 alone and in combination against systemic murine aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 41: 397, 2001

Combination posaconazole and amphotericin B therapy of murine pulmonary acute invasive aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 42: 416, 2002

Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrobial Agents and ChemoTherapy 51(4): 1253-1258, 2007

Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrobial Agents and ChemoTherapy 35(7): 1329-1333, 1991

The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis. Journal of Antimicrobial ChemoTherapy 65(2): 289-292, 2010

Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrobial Agents and ChemoTherapy 42(4): 873-878, 1998

Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model. Journal of Antimicrobial ChemoTherapy 64(2): 379-382, 2009

Efficacy of voriconazole plus amphotericin B or micafungin in a guinea-pig model of invasive pulmonary aspergillosis. Clinical Microbiology and Infection 10(10): 925-928, 2004

Efficacy of FK463, a novel water-soluble echinocandin-like lipopeptide, in murine models of pulmonary aspergillosis. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy 38: 268-269, 1998